Food and Drug Administration Commissioner Marty Makary resigns, with Kyle Diamantas stepping in as acting commissioner. Details from STAT's exclusive coverage.

Food and Drug Administration Commissioner Marty Makary has resigned from his role, according to an administration source familiar with the matter. President Donald Trump confirmed Makary’s resignation while addressing reporters ahead of a trip to China. "He's going to go on and he's going to lead a good life," Trump said of Makary. "He was having some difficulty. He's a great doctor. He's going to go on and do well. Everybody wants that job."

Kyle Diamantas, the top food regulator at the agency, will step in as acting commissioner.

STAT+ Exclusive Story Already have an account? Log in

To read the rest of this story, subscribe to STAT+. Subscribe Log In

The Readout May 12, 2026

STAT Plus: Hims' Sales Miss as Telehealth Competition Grows By Elaine Chen Biotech May 12, 2026

STAT Plus: Capsida Says It Still Doesn't Know What Caused Gene Therapy Death By Jason Mast Advertisement The Readout May 11, 2026

STAT Plus: Astellas Treatment Offers New Hope to a Devastated Rare Disease Community By Meghana Keshavan Health May 11, 2026

STAT Plus: Five Years After Disaster, a Rare Disease Community Gets New Chance at Treatment By Jason Mast Exclusive Exclusive May 11, 2026

STAT Plus: Medicare Is Spending Far Less Than Expected on New Alzheimer’s Drugs By Bob Herman STAT Plus: What Was Lost at the FDA By Lizzy Lawrence STAT Plus: Sanofi Asks to Pull Diabetes Drug Out of FDA Voucher Program After Political Appointee Interfered with Review By Lizzy Lawrence Why We Left the FDA: Six Former Officials Share Their Stories By Alex Hogan STAT Plus: Top Lawmaker Takes Aim at Doctor Lobby, Linking AMA’s Billing Codes to Fraud Fight By John Wilkerson

The resignation comes amid ongoing turmoil within the agency. Makary's departure follows a series of high-profile departures and controversies that have rocked the FDA in recent months.

Makary served as commissioner since 2017, overseeing critical decisions on drug approvals, medical device regulations, and public health initiatives. His exit marks a significant shift in leadership at one of the most influential agencies in healthcare policy.

Diamantas, who has been serving as deputy commissioner for operations since 2019, will now assume the top role until a permanent replacement is appointed by President Trump. The FDA's next steps and the implications of Makary’s departure are expected to shape future regulatory policies and public health initiatives moving forward.